PerkinElmer, Inc.
May 7, 2012

PerkinElmer Announces Agreement with Macrogen, Inc. to Provide Next Generation Sequencing Solutions

Global leader in life sciences solutions to supply high throughput NGS sample preparation instruments to Korean provider of gene analysis services for improved sequencing analysis

WALTHAM, Mass. – May 7, 2012 – PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment, today announced an agreement to provide Next Generation Sequencing (NGS) sample preparation solutions to Macrogen, Inc., a Korean-based global sequencing company.

As part of the agreement, PerkinElmer will provide Macrogen with its Sciclone® NGS Workstation for high throughput automated Next Generation Sequencing sample preparation, the LabChip® XT nucleic acid size selection and collection system,  and the  LabChip® GX nucleic acid separation system, to automate and increase the company’s sequencing analysis efficiency and throughput.

“We are delighted to assist Macrogen in its global mission to help realize the promise of understanding the human genome through its services, to advance better therapeutics and diagnostics for clinicians and patients worldwide,” said Kevin Hrusovsky, President, Life Sciences & Technology, PerkinElmer. “Our next generation sequencing solutions are well suited for helping to ensure the quality and integrity of genomic information for use in making personalized medicine a reality.” 

“Advanced automation-enabling technologies are becoming increasingly mission critical for effective and efficient interpretation and analysis of the human genome,” said Professor Jeong-Sun Seo, Chairman, Macrogen, Inc. “By applying PerkinElmer biotechnology solutions, Macrogen will be able to further strengthen its objective of providing high quality, best-in-class, next generation sequencing services to researchers and clinicians all over the world.”

“The key to success in leveraging genomic data is the ability to combine a high degree of accuracy, with efficient high throughput in order to generate efficiencies leading to lower costs. By assuring quality and speed through advanced automation for sample preparation and analysis, we can help provide researchers and clinicians with the insights they need to revolutionize medical treatment,” added Dr. Hyungtae Kim, Chief Executive Officer, Macrogen, Inc.  "We have purchased new NGS sequencers to meet these demands, which resulted in doubling our sequencing capacity. In turn, the introduction of these new instruments made it essential to introduce an advanced automation system, which drove our decision to select PerkinElmer solutions."

Key features of the PerkinElmer Next Generation Sequencing solutions for Macrogen include:

About Macrogen

Macrogen, Inc. (, based in Seoul, Korea, is a world leading service provider in high-quality gene analysis and has enjoyed stable and steady growth since 1997. The company’s diverse offerings include DNA sequencing, next generation sequencing, microarray analysis, oligonucleotide synthesis, and genetically engineered mice services. In addition, Macrogen has been expanding its business scope into other areas such as molecular diagnostics and consumer genomics. With a global presence, Macrogen operates through U.S. subsidiaries in Rockville, New York, and Cambridge; in the Netherlands in Europe; and, in Tokyo, Japan. Macrogen is listed on the Korea Securities Dealers Automated Quotation (ticker symbol: A038290).   

About PerkinElmer, Inc.

PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The Company reported revenue of approximately $1.9 billion in 2011, has about 7,000 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at

# # #

Media Contact:


Amanda L. Connolly
Edelman (On behalf of PerkinElmer, Inc.)
Phone: 404-832-6785